ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentMuttenzPerseo pharma AG
Perseo pharma AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Perseo Pharma AG is the development of enzyme replacement therapies for the treatment of metabolic diseases, in particular for rare diseases such as exocrine pancreatic insufficiency, congenital sucrase-isomaltase deficiency and maple syrup urine disease. The company develops innovative therapies based on the enzzen platform technology and focuses on the clinical development of active ingredients for the treatment of these diseases.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

Perseo pharma AG

Pharmaceutical Industry
✓ Offered5
Development of Enzyme Therapeutics
Development of oral enzyme therapies for digestive conditions, based on a proprietary nanotechnology platform with nano-shield and muco-adhesive coating.
Nanotechnology Platform for Oral Enzyme Therapies
Proprietary platform that protects enzymes in silica nanoparticles and an organo-silica layer, prolonging their residence time in the small intestine and maintaining activity.
Development of Therapies for Digestive Diseases
Research and development of therapies for exocrine pancreatic insufficiency, carbohydrate malabsorption, PKU, CSID and MSUD.
Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases
Research on systemic enzyme replacement therapies for lysosomal storage diseases as part of the second development wave.
Partnerships for the Co-Development of Innovative Therapies
Cooperations for the co-development of innovative therapies in the areas of metabolic therapies, onco-metabolism and systemic enzyme replacement therapies.
Trust & reputation

ranQ Trust Score of Perseo pharma AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 58% · As of October 2026

Perseo pharma AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Perseo pharma AG scores 78.6 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Perseo pharma AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Perseo pharma AG scores 16.5 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.22.94%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

Perseo pharma AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

May 15, 2019Media
INOFEA spins-off Perseo Pharma to further develop therapeutic enzymes
startupticker.ch

Knowledge

No knowledge articles yet

Once Perseo pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Perseo pharma AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Perseo pharma AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Perseo pharma AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hofackerstrasse 40B
4132 Muttenz

At a glance

Legal form
Corporation
UID
CHE-492.603.214
Founded
2019 · 7 years
Last commercial register change
October 24, 2025
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    IA
    INOFEA AG
    Muttenz
    NB
    Nanolynx Biologics AG
    Allschwil
    GG
    Gubra GmbH
    Allschwil
    IA
    InCephalo AG
    Allschwil
    SF
    Stiftung Forschung Klinik Arlesheim
    Arlesheim
    AP
    Actelion Pharmaceuticals Ltd
    Allschwil
    GG
    GlioCART GmbH
    Allschwil
    BP
    Bright Peak Therapeutics AG
    Allschwil